

BioHealth Innovation

www.biohealthinnovation.org

Founding Member





A Top 3 BioPharma Cluster in 2023 & 2024



Top 10 U.S. Biopharma Clusters 2024

Ranking Based on Five Criteria:

- 1. NIH Funding
- 2. Venture Capital Funding
- 3. Patents
- 4. Lab Space
- 5. Jobs

- 1. San Francisco Bay Area
- 2. Boston/Cambridge, MA
- 3. BioHealth Capital Region (Maryland/Virginia/DC Metro)
- 4. New York/New Jersey
- 5. Los Angeles/Orange County, CA
- 6. San Diego
- 7. Greater Philadelphia
- 8. Raleigh-Durham, NC (Inc. Research Triangle Park, NC)
- 9. Seattle
- 10.Chicagoland

#3 - 2024 BioHealth Capital Region (MD-VA-DC)

- 1st in Patents
- 3rd in NIH funding
- 3rd in Lab Space
- 3rd in Jobs
- 5th in VC Funding



"The BioHealth Capital Region leads the nation in patents (73,315 families) thanks to IP powerhouses like Johns Hopkins University, the NIH, and National Library of Medicine. The Maryland-Virginia-D.C. region placed third in NIH funding (5,558 awards totaling \$4.342 billion), jobs (136,164 according to BHCR based on data from labor market analytics firm Lightcast) and lab space with 35.9 million square feet according to BHCR based on data from JLL, whose figure includes the 9.2 million square feet of lab space within the NIH Campus headquarters in Bethesda, MD. In venture capital, BHCR cited PitchBook data showing the region climbing three notches year-over-year to fifth with \$1.92 billion in 2023 and \$1.01 billion in Q1–Q2 2024."- Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News

The Growth of the "BioHealth" Brand

- BioHealth Innovation
- BioHealth Capital Region
- Office of BioHealth Maryland Department of Commerce
- BioHealth Capital Region Genetic Engineering News
- Activation Capital's "Frontier BioHealth"
- Institute for BioHealth Innovation George Mason
- AURP BioHealth Caucus

- Wisconsin's BioHealth Industry
- Women in BioHealth U.W. Madison
- Growing BioHealth Cluster Ohio
- Luxembourg BioHealth Cluster
- South Korea BioHealth Industry
- Greece BioHealth Innovation Hub
- HIG BioHealth Fund
- BioHealth Sciences Oregon
- ibs.GRANADA BioHealth
- K•BIC Korea Biohealth Innovation & Start-up Center

IT ALL STARTED HERE!







BioHealth Capital Region: An Overview of the BHCR - Where You Should Be



Top Tier Research Universities

Including Johns Hopkins and the University System of Maryland provide a pipeline of talent & intellectual property

- 78 National Labs & Research Institutes
 Including NIH, ARL, NRL, and NASA Goddard that receive
 \$19 billion annually and provide technical talent and a pipeline of tested, commercializable technologies
- Regulatory & Governmental Bodies
 Including FDA, CMS, and HHS provide thought leadership in the ecosystem and insight into what changes are next
- Concentration of Science & Engineering Talent
 From universities, national labs, and government positions
 with the technical skills to launch high-tech startups,
 especially with licensed intellectual property
- Established Cluster of BioHealth Companies

 Over 2,300 BioHealth companies in BHCR from

 multinational corporations to cutting edge startups

BioHealth Innovation

Challenges to Innovation Economy

Lack of connection of innovation resources

Lack of an entrepreneurial culture & C-level executives

Lack of early-stage funding for commercializing technologies

Lack of spin-offs from federal & university R&D

Solutions for the Innovation Economy

Connect regional innovation assets

Develop an entrepreneurial talent & support pipeline

Attract funding for technology commercialization

Evaluate commercially relevant federal & university technology

Regional BioHealth Ecosystem Partners

ACADEMIA

- RESEARCH/T2
- LIFELONG LEARNING
- ECONOMIC DEVELOPMENT

INDUSTRY

- PROFIT
- PROCESS
- PRODUCT

INSEPARABLE MISSIONS

GOVERNMENT

- Sustainability
- INFRASTRUCTURE SUPPORT
 - ECONOMIC POLICY

FOUNDATIONS/NGOS

- ECONOMIC GROWTH
- COMMUNITY INVESTMENT
- REGIONAL COLLABORATION



BHCR Support Organizations





Richard A. Bendis President/CEO

"BHI sources and evaluates market-relevant biohealth intellectual properties, connects the IP with funding, andassists businesses in marketing and growth."





John Newby

"We fuel the network of leaders that drive bioscience to eradicate disease, save lives, and feed the world....one innovation at a time."





Kelly Schlutz CEO

"We are a collaborative community that is actively engaged in building strong technology and life science industries by supporting the efforts of our individual members."





Troy LeMaile-Stovall
CEO & Executive Director

"TEDCO provides framework of knowledge, funding, and networking to support an innovation eco-system that nurtures researchers, entrepreneurs, start-ups, and earlystage companies engaged in bringing innovation ideas to market."





Bill Thompkins President & CEO

"We are a premier destination with a powerful network of existing businesses across a wide range of industries. Our deep talent pool, diverse and vibrant communities, and proximity to the federal agencies including the Departments of Transportation and Energy, FDA, and NIH position the County's companies for success."




Johnson Johnson

Rachel Rath
Head of JLABS @ Washington, DC
At JLABS @ Washington, DC, we support early-stage life
science innovators with lab space, mentorship, and access to
Johnson & Johnson's network"

BioHealth Innovation: An Innovation Intermediary

A public-private partnership, serving as an innovation intermediary in the BioHealth Capital Region with a mission to:

- Advance local technologies, assets and resources
- Accelerate innovation
- Globally connect sectors, industries, communities, and markets



- Regionally, Nationally, and Internationally-Oriented
- Private-public partnership, 501(c)(3) nonprofit
- BioHealth Innovation Management, a for-profit subsidiary
- Market-driven, private sector-led and funded
- Neither a government initiative, nor a membership organization



BioHealth Innovation Board of Directors

Adventist HealthCare	John A, Sackett President & CEO Adventist Healthcare	Emmes	Peter Ronco CEO The Emmes Corporation	SOUTH FEDERAL CREDIT UNION	Rick Wieczorek President / Chief Executive Officer NIH Federal Credit Union
A L E X A N D R I A.	Joel Marcus Executive Chairman & Founder Alexandria Real Estate Equities	gsk	Steven Roberts Director, External R&D Scientist Collaborations GSK	ON DEMAND PHARMAGEUTICALS	Jarrod Borkat Chief Commercial and Strategy Officer On Demand Pharmaceuticals
AMGEN	Yaminah Leggett-Wells Senior Director, Alliance Management AMGEN	(())JLL	Pete Briskman (CHAIR) Executive Managing Director Lead Mid-Atlantic Life Sciences Practice Jones Lang LaSalle (JLL)	Phlow	Eric Edwards Co-Founder & CEO Phlow Corporation
BioHealth Innovation	Richard A. Bendis President & CEO BioHealth Innovation Inc.	Johnson&Johnson	Rachel Rath Head JLABS @ Washington DC	University System of Maryland	Dr. Jay Perman Chancellor University System of Maryland
- COTION -	Donna Edmonds (Vice Chair) Founder & CEO Brainbox Solutions	J.P.Morgan	Brett Shealy Executive Director of Life Sciences J.P. Morgan	usp	Anthony Lakavage Sr. Vice President, Global External Affairs US Pharmacopeia
Canon	Ronald Kurz Vice President, Business Development Group Canon Virginia, Inc.	Kelly	Sarah Porter Vice President Kelly Services	VENABLE (LP	Charles Morton (Secretary) Partner Venable, LLP
Deloitte.	Dr. Jessica Nadler Managing Director Deloitte Consulting, LLP	miRecule RAR Therapeutic	Dave Lemus (Treasurer) CFO/COO miRecule	United Therapeutics	Aimee Smart Vice President of Clinical & Regulatory Processes United Therapeutics
EMERGENT"	Jason Hall VP, Portfolio Management Emergent BioSolutions	M&T Bank	Christopher Callaghan Group Vice President Healthcare Banking M&T Bank		


































BioHealth Innovation Organizational Chart



Bench

BioHealth Technology Focus

- Therapeutics
- Diagnostics
- Medical Devices
- Healthcare Services
- E-Health
- Digital Health
- Electronic Medical Records
- Biomarkers and Tools
- Health Informatics
- BioHealth Cybersecurity
- Personalized Health
- Al, Machine Learning, Quantum









Innovation Paradigm Shift


PROOF OF CONCEPT
Technological Feasibility
(Laboratory Push)
"It Works!"



PROOF OF COMMERCIAL
RELEVANCE
(Market Pull)
"It Works To Solve A
Problem" "I'll Buy It"



State of Maryland: Federal & University Resources



- Population: 6.2 Million People
- 78 Federal Laboratories, Centers & Institutes in Maryland
- Maryland Federal R&D Investment Exceeding \$25 Billion Annually

JHU and USM represent another \$5 billion in annual R&D











Unrivaled Research Assets Unfulfilled Commercial Promise 800+ BioHealth Companies







































BioHealth Regional Innovation Cluster Assets





















































Major Regional BioHealth Companies































































Public BioHealth Companies Headquartered in the Region












































SEPTEMBER 23-24-25, 2025



The BioHealth Capital Region:


Where Human & Artificial Intelligence Converge in the BioHealth Industry






BioHealth Capital Region Forum

Registrants



Sponsors



2024 BHCR Week Highlights



Maryland Governor Wes Moore addresses the audience to open the 10th Annual BioHealth Capital Region Forum



Official Photo by the Office of Governor We Moore



John Crowley, President and CEO of Bio, Virginia Governor Glenn Youngkin, John Newby, CEO of Virginia BIO Official Photo by Christian Martinez, Office of Governor Glenn Youngkin



BHI's Rich Bendis, Linsholm's Talia Feldman, and Wilson Sonsini's Derrick Rowe



Robert Stoffel, VP of Rare Disease, Complex Biologics, and Strategic Technology Alliances at Amgen





Craig Gravitz, Director of the Project Accelerator Transition Innovation Office (PATIO) at ARPA-H

DISTINGUISHED JUDGES:





Rich Bendis MODERATOR
President & CEO
BioHealth Innovation, Inc.



Charles AndresShareholder
Greenberg Traurig, LLP.



Katherine Hill Ritchie
Senior Director, Venture Funds
TEDCO



Conley Jones
Principal- Science & Technology
Alexandria Real Estate Equities, inc./
Alexandria Venture Investments



Albine Martin
Co-Founder & Managing Director
Accelevir
Entrepreneur-in-Residence (BHI)



John Newby Chief Executive Officer Virginia Biotechnology Association



Derrick RowePartner
Wilson Sonsini Goodrich & Rosati



Brett ShealyExecutive Director, Life Sciences Banking
J.P. Morgan



Matt Tremblay
CEO
Blackbird Laboratories



CONSIDERATIONS

- Technical Feasibility & Intellectual Property
- · Commercialization & Marketing Strategy
- Leadership Team & Collaborations
- Funding to Date & Financial Projections

CRITERIA

- Demonstrated Proof of Concept
- Have received Funding (dilutive/nondilutive)
- Understanding Regulatory/Reimbursement Paths
- Clear Path to Market & Scalable

Crab Trap Partners:









Previous Crab Trap Winners

2024	Linshom Medical Every Breath Counts	<u>Linshom Medical</u> offers the first wearable, FDA-cleared device providing a continuous, real-time respiratory profile at the bedside, monitoring key metrics to identify respiratory decline up to 70 minutes before an emergency and improving patient outcomes.
2023	LUMINOAH	<u>Luminoah</u> is a MedTech company on a mission to revolutionize the enteral feeding market with a wearable system that combines durable medical equipment, consumable nutrition pouches, and remote patient monitoring to optimize compliance and clinical outcomes.
2022	NEUR WENE THERAPEUTICS	<u>Neuroene Therapeutics</u> was founded to develop a drug discovery platform for mitochondrial dysfunction diseases, with a patent portfolio covering numerous analogs and pending patents covering hundreds of analogs aimed at the treatment of numerous disease indications and the corresponding methods.
2021	NANOCHON*	Nanochon is innovating a 3-D printed implant that replaces cartilage, fosters tissue growth, and aims to redefine cartilage restoration in healthcare.
2020	Brain Sc o pe°	BrainScope FDA-cleared portable EEG device triages head-injury patients for brain bleeds and concussions.
2019	floreo	Floreo uses virtual reality to teach real-world skills to individuals with autism and other developmental challenges.
2018	GALEN ROBOTICS	Galen Robotics designs a surgical robot that assists surgeons in performing precise, minimally invasive interventions while mitigating hand shakiness.
2017	LIFESPROUT	<u>LifeSprout</u> develops synthetic soft tissue substitutes for aesthetic and reconstructive medicine, promoting tissue regrowth without the need for tissue transfers.
2016	♦ SONAVEX	Sonavex, pioneers automated ultrasound technology for improved surgical outcomes, offering clinicians actionable data and cost savings

BioHealth Capital Region Serial Entrepreneurs



Mark P. Clein

- Precision for Medicine, Inc.
- United BioSource Corporation
- Infoscriber Corporation
- U.S. BioServices, Inc.



James S. Gammie, MD

- Correx, Inc.
- Harpoon Medical



Murat V. Kalayoglu

- Cartesian Therapeutics
- Topokine Therapeutics
- HealthHonors Corporation



Anthony Saleh

- miRecule
- Mimetas
- BioHealth Innovation



Rachel King

- GlycoMimetics
- NEA
- Genetic Therapy, Inc.



Ethan D. Leder

- Precision for Medicine, Inc.
- United BioSource Corporation
- U.S. BioServices, Inc.



Michael Richman

- NextCure
- Amplimmune



Martine A. Rothblatt Ph.D., J.D.

- United Therapeutics Corporation
- GeoStar
- SiriusXM Satellite Radio



Wendy Perrow

- AsclepiX Therapeutics
- Alba Therapeutics Corporation



Steve Turner

- Protea Biosciences Group, Inc.
- Clinomics BioSciences Inc.
- **Quorum Sciences**



Peter Greenleaf

- Aurinia
- Cerecor
- Sucampo
- MedImmune



Bill Enright

- · Gravitas Therapeutics Inc.
- **Barinthus Biotherapeutics**
- Avidea Technologies
- Altimmune Inc.




BHI Commercialization Model

This commercialization model shows the steps and partners that are involved in the BHI commercialization and support process.

The process below leads to the creation of new companies, spin-outs and strategic partnerships.


BHI connects companies with a network of public, private and academic entities.



NIH Partnership Agreements



NIH Consulting Entrepreneur Services Contract for NIH Entrepreneurs-in- Residence







PIA between BHI and NIH's SEED Office that supports the 27 NIH institutes and an extramural research budget of tens of billions to **promote and foster cooperative research and accelerate technology commercialization** among NIH businesses, and universities.



Supporting BioHealth Commercialization

BIOHEALTH INNOVATION, INC. (BHI) is a public-private, nonprofit 501(c)(3) organization focused on accelerating the commercialization of BioHealth technologies (including therapeutics, diagnostics, vaccines, medical devices, digital health, and artificial intelligence) in the BioHealth Capital Region (MD, DC, VA), US, and globally. BHI and its team of experienced EIRs have supported universities, entrepreneurs, and government agencies to accelerate biohealth technology commercialization.

ENTREPRENEUR-IN-RESIDENCE (EIR) CAPABILITIES - Over the past decade, BioHealth Innovation has developed a pool of committed and experienced BHI executives capable of supporting every need of a life science company, entrepreneur, academic researcher, or a government-funded project, including:

- Fractional CXO Support
- Fundraising Strategy
- Pitching Coaching
- Go-To-Market Strategy
- Business Development
- International Soft-Landing
- US Marketing Entry Strategy
- Partner/Deal Sourcing

- Regulatory Strategy
- Clinical Plan Development
- Reimbursement Strategy
- Intellectual Property Support
- Strategic Partner/KOL Identification
- Quality Support
- Health Economic & Outcomes

- Health Economic & Outcomes Research (HEOR)
- Development of Value Proposition(s)
- Product Differentiation
- Cybersecurity
- Artificial Intelligence (AI)

ANALYST TEAM CAPABILITIES:

Secondary & Primary Market Research • Market Validation • Competitive Analysis • Grant Mapping/Non-Dilutive Funding Support



Montgomery County Executives in Residence

Montgomery County is funding BHI's work as part of its mission to grow the local life sciences cluster

Launched in November 2022 – inspired by BHI's well-regarded NIH program, which features over a dozen experts in various disciplines, embedded within different institutes.

Goal is to provide impactful, life-sciences-specific services to a few local companies, opposed to general

business assistance to many.

"MoCo" EIRs may provide:

- Technology validation
- Assistance with customer discovery
- Regulatory and reimbursement strategies
- Market assessment
- Non-dilutive funding assistance
- Other assistance to launch and/or advance the business.

Montgomery County is also **funding** assistance from specialized experts, attorneys, and regulatory experts that cannot be provides by EIRs




Luis Gutierrez Kevin Heller



Jonathan Kay



Ien Butler





Deanne Randolph



Steve Wolpe

Any early or growth-stage BioHealth company headquartered in Montgomery County may be eligible for free assistance


Exclusive BHI EIR Partnership with ARPA-H

BHI signed a PIA agreement with the ARPA-H, a \$1.5 Billion HHS Institute, to provide EIRs to their performers

- BHI is providing part-time EIRs to ARPA-H funded Performers and Program Managers which started December 2023.
- **2. Strategic Collaboration:** BHI and ARPA-H have joined forces to enhance the development and commercialization of innovative health solutions.
- **3. Entrepreneurs-in-Residence (EIRs):** BHI will provide EIRs with strategic guidance to ARPA-H Program Managers in crucial areas such as technology development, intellectual property, and small business needs.
- **4. Bridge to Market Realization:** The partnership aims to bridge the gap between innovation and market realization, ensuring that transformative health solutions reach those who need them most.
- 5. Embedded Support: EIRs will provide embedded support to ARPA-H funded performers, assisting in business plan development, commercialization strategy, market research, and more.
- **6. Transition to Market:** EIRs will actively contribute to the transition of ARPA-H funded solutions into the market and identify new programs aligned with ARPA-H's primary mission.
- 7. Learn More: To explore this exciting collaboration further, read full announcement.



Innovation Capital Valley of Death





Meet Our Team BioHealth Innovation



Rich Bendis President & CEO



Lynne Brisbane VP Finance, HR, Operations



Jem Haskin Finance, HR, Operations



Jon Nelson Manager of Client Engagement



Kelly Murphy Life Science **Business** Strategist/Program Manager



Mona Suliman Life Science **Business Strategist**



Bennett Senior Life Science **Business Strategist**



Catherine Leasure Life Sciences Business Strategist



Oliva Meyer NIH/OER Life Science Business Strategist



Andy Eckert Communications & Marketing



JT Koffenberger IT/Systems

Entrepreneurs in Residence



ARPA-H EIR





ARPA-H EIR

Charles Buchen NIH/NIA/EIR



Chris Mathia ARPA-H EIR



Jennifer Butler Executive in Residence

Albine Martin

BHI/JHU/EIR



Kimberly Martin ARPA-H EIR



ARPA-H EIR

Kuldeep Nolte

NIH/NIA/EIR



APRA-H EIR



Quan Nguyen ARPA-H EIR



Executive in Residence



Deanne Randolph Executive in Residence



John Hsu Executive in NIH/NHLBI/SEED



Maureen Richard ARPA-H EIR



Jonathan Kay Executive in Residence



Loleta Robinson **Ethel Rubin** ARPA-H EIR



NIH/OER/EIR



Michael Thomas

ARPH-A EIR



Kwame Ulmer






ARPA-H





BioHealth Innovation EIRs & Strategists Team



MoCo,MD

BHI Federal Funding Assistance

- \$5 billion annual United States Government program coordinated by the Small Business Administration provides grants or contracts to small businesses to spur technological innovation
- Grants awarded in 3 phases between \$150,000 and \$4.0 million
- Non-dilutive





BHI SBIR/STTR Assistance Program Overview

BioHealth Innovation, Inc. (BHI) is a leader in providing SBIR/STTR assistance to growth stage companies ready to advance their healthcare initiatives and commercialize new technologies. BHI works with our clients from beginning-to-end to provide a customizable experience dependent on their specific needs.

BHI boasts a **3x** win rate compared to the national average!

SERVICES OFFERED

Full Development Program

BHI provides in-depth help throughout the entire writing, submission, and resubmission process. This includes (but is not limited to) strategizing, crafting specific aims and overall narrative, managing communication with program officers, developing the budget, and drafting components of the grant.

This program is project-based, not hourly-based.

Targeted Development Program

BHI commits to 10-20 hours providing feedback and general advice, editing research and commercialization plans, reviewing the budget, assisting with grant administration and rules, and advising on general strategy.

Grant Mapping

Whether you possess grant writing skills or not, identifying the right funding opportunity for your specific goals and situation can be challenging. BHI helps support companies in finding non-dilutive funding through federal and non-government organizations to fuel your success, delivering options tailored to your unique circumstances.



BHI Commercialization Support

Market Research

Our comprehensive market research service empowers life science companies to make informed decisions as they bring their innovations to market. We conduct in-depth analyses of industry trends, competitor landscapes, and potential customer segments to identify lucrative opportunities and potential challenges. Our expert team utilizes cutting-edge research methodologies to gather actionable insights, helping you refine your value proposition, optimize your go-to-market strategy, and maximize your technology's commercial potential. With our tailored market research, you'll gain the knowledge and confidence to navigate the complex life sciences marketplace effectively.

Maryland Innovation Initiative - Commercialization Support

We provide expert guidance throughout the commercialization process, helping awardees transform their groundbreaking research into market-ready products. Our services include refining business strategies, conducting targeted market research, and developing compelling investor presentations. By leveraging our industry expertise and extensive network, we enable MII recipients to navigate the complex path from lab to market, significantly enhancing their chances of commercial success and accelerating the timeline to market entry.



University Commercialization Support







GEORGETOWN UNIVERSITY



University of California San Francisco









INTERNATIONAL COLLABORATION: BHI'S 3-YEAR MENTORSHIP PROGRAM FOR 15 KOREAN COMPANIES

BHI-KOSME US Market Entry Program

To create a viable strategy for international expansion by understanding the competitive landscape in the US, clarifying a company's value proposition, identifying new target markets, and refining the business model.

KOSME is a Korean-government-funded non-profit created over forty years ago to support small and medium enterprises in Korea.

In 2021, 2022, and 2023, cohorts of five Korean companies participated in a 12 to 20-week BHI program to accelerate their entrance into the US.

The cohorts:

- Attended virtual lectures from subject matter experts,
- Received 1:1 and group mentoring from BHI's EIRs,
- Completed assignments, presentations and milestones;
- · Connected with strategic US partners and relevant networks; and
- Participated in the annual BioHealth Capital Region Forum and the Crab Trap pitch competition.











Tunisia FHI360 CURES Program

Tunisia lacks a central, international hub for teaching, research, simulation, innovation, and technology commercialization. To address this gap, FHI 360 is implementing the Tunisian Health Center for University Research Excellence & Sustainability (CURES) project, a 3-year initiative funded by the U.S. Department of State.



Joey R. Hood United States Ambassador to Tunisia



Yosra Koroui Technical Project Director

BHI is FHI 360's CURES partner, which includes building a foundation for market-relevant research, integrating a strong university technology transfer office, and educating stakeholders on the role that intellectual property plays in translating research from the lab to the patient.



Kawthar Ayedi Technical Advisor



lan Proctor BHI CURES Consultant













BHI International Soft-Landing Program

- U.S Subsidiary/Corporation Creation
- Business Development and Market Analysis
- Grant Funding/Non-Dilutive Funding Assistance
- Human Resource and General Administration Support
- Marketing and Promotion
- Pricing and Reimbursement
- Regulatory
- Resource Identification





International Company Requirements for U.S. Non-Dilutive Funding


- Company must be 50% controlled and owned by Americans
- Board of Directors must be controlled by Americans
- Most of the funded research must be performed in America

How to qualify:

- Form a U.S. Controlled subsidiary with trusted partners
- Create exclusive cross license agreement between new sub and parent for any new IP and technology created under grant funding
- Hire new U.S. management to manage new subsidiary or form partnership with a U.S. entity like BHI to manage
- Engage U.S. law firm familiar with above structures



BHI International Soft-Landing





BioTalk with Rich Bendis

BioTalk with Rich Bendis" is a BioHealth leading podcast featuring conversations with Bio and Healthcare Industry leaders. For the past 7 years, with 160+ episodes and over 50,000 downloads, Rich Bendis, Founder, President, and CEO of BioHealth Innovation Inc. (BHI) and host of BioTalk, has provided a platform for guests to discuss and share their views on the most important topics and developments happening today in the BioHealth industry.



The BioTalk podcast is featured on leading podcast platforms, including:



Apple Podcasts









Showcasing leading and emerging BioHealth hubs, including Boston, San Francisco, NYC, BioHealth Capital Region, San Diego, RTP, Seattle, Texas, and Canada.

Previous Guests Include:

- **Joel S. Marcus**, Executive Chairman & Founder, Alexandria Real Estate Equities, Inc.
- **Peter S. Briskman**, Executive Managing Director, Brokerage, Jones Lang LaSalle IP, Inc. (JLL)
- Anthony S. Fauci, M.D., Former Director of the National Institute of Allergy and Infectious Diseases (NIAID)
- Ron Piervincenzi, Ph.D., CEO of United States Pharmacopeia (USP)
- Jay A. Perman, MD, Chancellor, University System of Maryland (USM)
- Mr. Hakdo Kim, President, Korea SMEs & Startups Agency (KOSME)

- Sally Allain, MSc., MBA, Head, Johnson & Johnson JLABS @ Washington, DC
- Alex Philippidis, Senior News Editor, Genetic Engineering and Biotechnology News
- **Gary Disbrow, Ph.D.**, Director of the Biomedical Advanced Research and Development Authority (BARDA)
- Anthony D. Saleh, Ph.D., CEO, miRecule
- Paul Vulto & Jos Joore, Co-Founders, Mimetas
- Joey R. Hood, U.S. Ambassador to the Republic of Tunisia
- Michelle Tarver, M.D., Deputy Center Director, Chief Transformation Officer
- Center for Devices and Radiological Health (CDRH), US Food and Drug Administration



Website, News & More



BHI Website

The BHI website has news, an events calendar, research publications, regional organization feature stories and resources for the biohealth industry.

www.biohealthinnovation.org



BHI News

BioHealth Innovation

BeneVir Prison

BHI Celebrates Funding Successes of Clients

BeneVir BioPharm, Inc. and Perceptive Navigation LLC Schrooth Innovation, Inc. (BHI), a regional private-public partnership focusing or commercializing market-relevant bioheath innovations and increasing access to

early-stage funding in Central Maryland, today announced recent highlights of funding achievements for clients, Bene' ir Biopharm, Inc., and Perceptive Navigation, LLC, The significant progress polices both companies for clinical and/or

with Rich Bendis

BHI's weekly e-newsletter highlights the Central Maryland region's news articles, national biohealth trends and feature stories.

www.biohealthinnovation.org/news

www.biohealthcapital.com

BioTalk

Rich Bendis, hosts BioTalk — conversations with some of the most accomplished and exciting business, academic, and government leaders in the biohealth industry.



BHI Contact

1 Church Street, Suite 801 Rockville, MD 20850 301-637-7950

<u>info@biohealthinnovation.org</u> <u>www.biohealthinnovation.org</u>



